GILD
Gilead Sciences·NASDAQ
--
--(--)
--
--(--)
GILD fundamentals
Gilead Sciences (GILD) released its earnings on Feb 10, 2026: revenue was 7.92B (YoY +4.70%), beat estimates; EPS was 1.86 (YoY -2.11%), beat estimates.
Revenue / YoY
7.92B
+4.70%
EPS / YoY
1.86
-2.11%
Report date
Feb 10, 2026
GILD Earnings Call Summary for Q4,2025
- HIV Dominance: 2025 HIV sales up 6% to $20.8 billion, with Yeztugo on track for $800 million in 2026.
- Liver Leadership: Livdelzi captures 50% U.S. market share in second-line PBC, driving 6% liver business growth.
- Oncology Breakthrough: Trodelvy poised for first-line TNBC approval in 2026, supported by 15-month OS in Phase II trial.
- Pipeline Power: 4 potential 2026 launches and 5 Phase III readouts position Gilead for sustained growth.
- Financial Strength: 2026 guidance for $29.6-30 billion in sales, 87% gross margin, and $8.45-8.85 EPS, with disciplined expense management.
EPS
Actual | 1.68 | 1.11 | 2.11 | 2.19 | 2.08 | 1.87 | 2.65 | 0.69 | 2.12 | 1.58 | 1.9 | 1.67 | 1.37 | 1.34 | 2.29 | 1.72 | -1.32 | 2.01 | 2.02 | 1.9 | 1.81 | 2.01 | 2.47 | 1.86 | ||||||||||||||||
Forecast | 1.5741 | 1.4437 | 1.9521 | 2.0382 | 2.0782 | 1.7394 | 1.7574 | 1.5931 | 1.8043 | 1.5159 | 1.4256 | 1.5179 | 1.5234 | 1.6425 | 1.9164 | 1.7584 | -1.4932 | 1.6074 | 1.53 | 1.7375 | 1.7804 | 1.9601 | 2.1321 | 1.81 | ||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +6.73% | -23.11% | +8.09% | +7.45% | +0.09% | +7.51% | +50.79% | -56.69% | +17.50% | +4.23% | +33.28% | +10.02% | -10.07% | -18.42% | +19.49% | -2.18% | +11.60% | +25.05% | +32.03% | +9.35% | +1.66% | +2.55% | +15.85% | +2.76% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.55B | 5.14B | 6.58B | 7.42B | 6.42B | 6.22B | 7.42B | 7.24B | 6.59B | 6.26B | 7.04B | 7.39B | 6.35B | 6.60B | 7.05B | 7.12B | 6.69B | 6.95B | 7.54B | 7.57B | 6.67B | 7.08B | 7.77B | 7.92B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.45B | 5.29B | 6.29B | 7.08B | 6.74B | 6.08B | 6.29B | 6.61B | 6.29B | 5.86B | 6.13B | 6.64B | 6.33B | 6.45B | 6.81B | 7.10B | 6.36B | 6.70B | 7.02B | 7.15B | 6.81B | 6.98B | 7.45B | 7.69B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +1.81% | -2.73% | +4.63% | +4.80% | -4.72% | +2.28% | +18.00% | +9.51% | +4.85% | +6.80% | +14.87% | +11.36% | +0.32% | +2.25% | +3.51% | +0.20% | +5.17% | +3.75% | +7.55% | +5.82% | -2.11% | +1.44% | +4.35% | +3.05% |
Earnings Call
You can ask Aime
What guidance did Gilead Sciences's management provide for the next earnings period?What does Gilead Sciences do and what are its main business segments?What factors drove the changes in Gilead Sciences's revenue and profit?What were the key takeaways from Gilead Sciences's earnings call?What is the market's earnings forecast for Gilead Sciences next quarter?What were the key takeaways from Gilead Sciences’s earnings call?Did Gilead Sciences beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Gilead Sciences year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
